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Abstract
The efﬁciency and accuracy of different methods for quality control of radiopharmaceutical preparations for diagnostic purpose were
studied. The radiochemical purity of 99mTc Tetrafosmin, 99mTc Exametazime, 99mTc Sestamibi and 99mTc Oxidronate was evaluated by
different thin layer chromatography systems, followed by cutting of the strips into two or three sections and by the measurement of
radioactivity distribution by dose calibrator or gamma counter. In addition, to conﬁrm the accuracy of these routine procedures, the
strips were cut into a number of micro-sections (14–25) and each of them evaluated by the gamma counter.
The three tested procedures gave similar results and revealed a good and comparable accuracy. The radioactivity measurement with
the dose calibrator remains the most practicable because of the rapidity of execution.
r 2007 Elsevier Ltd. All rights reserved.
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1. Introduction
Use of radiopharmaceuticals in vivo needs radiochemical
purity testing to be carried out just before administration
to the patient. The methods used for quality control should
not only be characterised by the highest accuracy and
reliability, but should also be easy to perform and handle,
safe and quick in order to ensure the use in a busy
laboratory or in emergency situations (Dewanjee, 1990).
Exametazime [(RR,SS)-4,8-diazo-3,6,6,9-tetramethyl-
undecane-2,10-dione bisossime) (HM-PAO) is a highly
lipophylic compound able to form a complex with 99mTc
and is mainly used for cerebral perfusion studies (Ballinger
et al., 1988, 1990) or via administration of labelled
leukocytes for the diagnosis of inﬂammatory pathologies
and infections (Bertrand-Caix et al., 1996). Exametazime
may exist as the pharmacologically active isomeric forms
D,L and as the inactive meso form that must be removed
from the precursor before use.
Mibi (2-methoxy-isobutyl-isonitrile)Cu(I) tetraﬂuorobo-
rate) is a large synthetic molecule of the isonitrile family,
which can be labelled with 99mTc to form a complex with
the Tc atom surrounded by six 2-methoxy-isobutyl-
isonitrile)Cu(I) tetraﬂuoroborate groups (99mTc Sestamibi)
(Hung et al., 1991). 99mTc Sestamibi was introduced in
1984 and has been used in clinical trials since the late 1980s
(Munch et al., 1997; Taillefer, 1999; Lombardo et al.,
2006). This molecule is a monovalent cation which passes
cells membranes passively, the driving force being the
negative membrane potential. Once intracellular it further
accumulates in the mitochondrias where the membrane
potential is even lower. 99mTc Sestamibi is a radio-
pharmaceutical used for the study of myocardial perfusion.
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99mTc Tetrofosmin (1,2-bis[bis(2-ethoxyethyl) phosphi-
no] ethane) (Myoview) is a cationic lipophylic cardiac
imaging agent, useful in the diagnosis and localisation of
regions of reversible myocardial ischaemia in the presence
or absence of infarction under exercise and rest conditions
(Munch et al., 1997; Nakajima et al., 1993). It is an
alternative Tc-based synthetic imaging agent with proper-
ties, doses, administration protocols and diagnostic accu-
racy similar to Sestamibi (Lombardo et al., 2006). 99mTc
Sodium Oxidronate (99mTc HDP) is a radiopharmaceutical
used for bone scintigraphy as it labels areas with impaired
osteogenesis.
The aim of this paper was to evaluate in terms of
efﬁciency, accuracy and rapidity, three different procedures
to test the radiochemical purity of 99mTc Tetrafosmin,
99mTc Exametazime, 99mTc Sestamibi, 99mTc Oxidronate,
prepared just before the administration to the patients.
2. Materials and methods
The following drugs were used: 99mTc Exametazime
(99mTc HM-PAO) [(RR,SS)-4,8-diazo-3,6,6,9-tetramethyl-
undecane-2,10-dione bisossime)] (CERETEC V9A A01
ESAMETAZIMA, kit for the preparation of 99mTc
Exametazime, Amersham Plc., Buchs, UK), 99mTc Tetra-
fosmin (MYOVIEW, kit for the preparation of 99mTc
Tetrafosmin, Amersham plc), 99mTc Sestamibi (2-methoxy-
isobutyl-isonitrile)Cu(I) tetraﬂuoroborate) (Cardiolite, kit
for preparation of 99mTc Sestamibi, The Wellcome
Foundation Ltd., London, UK), 99mTc Oxidronate
(99mTc hydroxymethylene diphosphonate) (99mTc HMDP)
(OSTEOCISs, kit for the preparation of 99mTc Oxidro-
nate, CIS Bio International, Gif-Sur-Yvette CEDEX,
France).
Lyophilised radiopharmaceuticals were reconstituted as
suggested by manufacturers by qualiﬁed and expert
technicians, following the requirements of radiological
safety and under the supervision of a nuclear medicine
physician. The drugs were reconstituted under stringent
aseptic conditions.
2.1. Protocol for radio-purity determination of 99mTc
Exametazime (99mTc HM-PAO)
The preparation for i.v. injection of Exametazime can be
potentially contaminated by a secondary complex of 99mTc
Exametazime, by free pertechnetate, by hydrolyzed and
reduced 99mTc. To fully deﬁne the chemical composition of
the i.v. preparation two different chromatographic systems
were used. About 3 mL drop of the reconstituted drug was
placed with a glass capillary at 2.5 cm from the bottom of
two istant thin layer chromatography/silica gel (ITLC/SG)
strips (Gelman, 2.5 20 cm) labelled with different colours.
The strips were immediately placed in a TLC chamber
containing either 1.5mL of methylethylketone (system A),
or sodium chloride 0.9% (system B) as mobile phase. After
the solvent front reached the end-point (15 cm from the
bottom), the strips were removed, dried, cut at the middle
(Rf ¼ 0.5) and the two sections (top and bottom) crushed
within a 30mL syringe, in order to make the geometry
more homogeneous before radioactivity counting. In
system A, the lipophylic complex 99mTc Exametazime
and the free pertechnetate migrates with Rf ¼ 0.8–1.0,
while the secondary complex of 99mTc Exametazime and
the hydrolyzed and reduced 99mTc do not move from the
origin and could be calculated as
A% ¼ Ab  100
AT
,
AT was the total TLC activity ¼ At+Ab, where At is the
activity of the upper part (top), Ab the activity of the lower
part (bottom).
In system B, only the pertechnetate migrates with
Rf ¼ 0.8–1.0, while the other three molecules remain at
the origin. In the same way from system B, the % of free
pertechnetate in the upper part of the strip could be
calculated as B% ¼ Bt 100/BT. The radiochemical purity
of the lipophylic complex 99mTc Exametazime was calcu-
lated as 100(A%+B%). This value must be above 80%,
proved that the drug is sampled and analysed within 30min
from the reconstitution.
2.2. Protocol for radio-purity determination of 99mTc
Sestamibi
A 3 mL drop of ethanol was placed at 1 cm from
the bottom of a pre-cut aluminium oxide TLC strip
(Baker-Flex strip # 1 B-F, 2.5 7.5 cm) with a glass
capillary and immediately after, avoiding ethanol drying, a
3 mL drop of 99mTc Sestamibi was spotted on the top of
ethanol spot and it was allowed to dry without heating
(5min). The strip was then placed in a developing
chamber (a 100mL beaker, containing 5mL of 95%
ethanol, covered with Paraﬁlms for 10min to equilibrate
C system A) and left until the solvent front reached the
5 cm end-point The strip was then cut at 4 cm from the
bottom and the two parts (top and bottom) treated as
described above for radioactivity counting. The radio-
chemical purity of 99mTc Sestamibi was calculated as
At 100/AT. The drug purity must be490% otherwise the
preparation will be discharged.
2.3. Protocol for radio-purity determination of 99mTc
Tetrafosmin
A Gelman ITLC/SG strip (2 20 cm) was marked at
3 cm from the bottom (origin) and at 3 cm (Rf ¼ 0.2), 12 cm
(Rf ¼ 0.8) and 15 cm (solvent front) from the origin.
A 10 mL drop of the reconstituted drug was placed at the
origin with a glass capillary and avoiding the spot to dry,
the strip was put immediately into the developing chamber
(a 100-mL glass cylinder covered with Paraﬁlms) contain-
ing system A (10mL of acetone:dichlorometane mixture,
35:65, v:v). When solvent front reached to the 15 cm mark
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(10min), the strip was removed from chamber, allowed to
dry and then cut at the three marks in three sections
(bottom, medium and top). Each section were treated as
above for radioactivity counting. The free pertechnetate
migrates to the upper part of the strip; the 99mTc
Tetrafosmin migrates at the middle of the strip while the
reduced 99mTc Tetrafosmin and the hydrophilic impurities
do not move from the origin. The radiochemical purity of
99mTc Tetrafosmin was calculated as Am 100/AT, where
Am is the activity of the medium part. The radiochemical
purity must be 490%, otherwise the drug preparation
must be discharged.
2.4. Protocol for radio-purity determination of 99mTc
oxidronate (99mTc HMDP)
A 10 mL drop was placed with a syringe at 2.5 cm from
the bottom of two ITLC-SG Gelman strips (2.5 20 cm)
and dried under ﬂow of nitrogen. Strips were placed into
two developing chambers containing system A (NaCl
0.9%, 5mL) and system B (1:1 methanol:acetone, v/v),
respectively. After the solvent front reached the end point
(17 cm from the bottom), the strips were removed and
allowed to dry. The strip A was cut at Rf ¼ 0.1 and the
strip B at Rf ¼ 0.9. Each parts were treated as before for
radioactivity counting. The % of hydrolyzed pertechnetate
was calculated from strip A as: A% ¼ Ab 100/AT. The %
of free pertechnetate was calculated from strip B as:
B% ¼ Bt 100/BT. The % of 99mTc bound to HMDP
(radiochemical purity) was calculated as 100(A%+B%).
The radiochemical purity must be 495%.
2.5. Radioactivity counting
The radiochemical purity was evaluated by measuring
for 1min the radioactivity of the different sections of the
TLC strips with the Doses Calibrator (ISODOSE ACN,
ACN, Italy), or with the gamma-counter COBRA II Auto-
Gamma (Packard Bioscience Company, UK) set on the
99mTc window. Due to the very high sensitivity of this
instrument and to avoid saturation it was necessary to
wait for 24 h before counting. As an alternative, to conﬁrm
the accuracy of above described routine procedures, the
radioactivity distribution was evaluated by cutting the
strips in 15–25 small sections (Fig. 1) and each of them
evaluated by the gamma counter. The background was
always subtracted from each measurement.
3. Results and discussion
The radiochemical purity (%) of the studied pharma-
ceuticals was not statistically different (Student t-test) when
calculated with the three different measurement procedures
(Table 1).
The dose calibrator is an instrument based on the use of
a ionisation chamber for radioactivity counting, and is
characterised by a background of 0.01–0.23MBq. While
the activity of the TLC sections containing the intact
compound was always higher than fourfold the SD of the
baseline noise, the radioactivity levels found in the strip
pieces containing the contamination by-products, were
closer to this background, suggesting a lower counting
precision on these pieces and a possible overestimation of
ARTICLE IN PRESS
0 16
R
a
d
io
a
c
ti
v
it
y
 (
c
p
m
)
0
0 2 4 6 8 10 12 14 16 18
R
a
d
io
a
c
ti
v
ty
 (
c
p
m
)
0
10x109
0 5 10 15 20 25
R
a
d
io
a
c
ti
v
it
y
 (
c
p
m
)
0
0 2 4 6 8 16
R
a
d
io
a
c
ti
v
it
y
 (
c
p
m
)
0
6x109
5x109
4x109
3x109
2x109
1x109
2x109
4x109
6x109
8x109
10x109
12x109
99mTc-Oxidronate
60x109
50x109
40x109
30x109
20x109
99mTc-Exametazime
99mTc-Sestamibi
99mTc-Tetraphosmine
20x109
16x109
12x109
8x109
4x109
Section numberSection number
Section number Section number
2 4 6 8 141210
141210
Fig. 1. Radioactivity distribution of 99mTc Oxidronate, 99mTc Exametazime, 99mTc Tetrafosmin, 99mTc Sestamibi evaluated by Gamma counter after
cutting of TLC strips into many micro-sections. Chromatographic conditions for each drug are described in the text under Section 2. The triangles in
Oxidronate and Exametazime plots refer to radioactivity distribution in TLC system B.
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radiochemical purity with this method. However, this was
not the case as quality control analysis performed with
dose calibrator never revealed signiﬁcant differences with
results obtained with the gamma counter or with the
radioactivity distribution analysis.
The COBRA II Auto-Gamma counter is an instrument
characterised by high accuracy and precision (counting
efﬁciency for 99mTc ¼ 50%, CVo0.1%), thus the activity
of the TLC sections containing the intact preparation
(4106 cpm) saturated the instrumental range and it was
necessary to wait about 4 half-life of 99mTc (about 24 h)
before counting. This excluded its use in the clinical
practice where the radiochemical purity must be assessed
immediately after the drug preparation and before the
administration to the patient.
In Fig. 1 is reported the radioactivity distribution
obtained after cutting the TLC strips into slides and
counting with the Gamma counter. The radioactivity
purity in this case was calculated as sum of the activity
of the different slides constituting the sections described
under Section 2. The procedure for the evaluation of the
radioactivity distribution was the more accurate one, with
a performance comparable to the one obtained by using a
chromatoscanner for the direct radioactivity distribution
evaluation (data not shown), but is impaired by the long
time needed for cutting the TLC strips into many different
slices and by the lag-time of 24 h necessary before counting
with the Gamma counter.
The three procedures used for the quality control
evaluation of radiopharmaceuticals to be used for diag-
nostic purpose, indicated a radiochemical purity always
higher than the reference allowed value for all the
preparations and no signiﬁcant differences were evidenced
between results (mean7SD) obtained with the different
radio-analytical methods. However, for 99mTc HMPAO
the method using the Gamma counter indicated a purity
slightly lower than the target (80%), thus resulting in a
reject batch. This is probably attributable to the very high
instability of the 99mTc HMPAO complex (manufacturers
suggest the use within 30min from the preparation) and to
the long waiting period (24 h) necessary before radio-
activity counting can be done by gamma counter.
In conclusion, the dose calibrator was the faster
instrument (measure time 1min) and being present in
all Nuclear Medicine departments, stands as the most
convenient technique for the clinical use.
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Table 1
Radiochemical purity of Tc drugs calculated with different testing methods
Drug Radiochemical purity (%)
Dose calibrator Gamma counter Radioactivity distribution Reference valuesa
99mTc Tetrofosmin 97.971.0 (n ¼ 15) 96.670.5 (n ¼ 10) 97.970.5 (n ¼ 3) 495
99mTc Exametazime 84.771.5 (n ¼ 15) 79.770.1 (n ¼ 10) 81.670.2 (n ¼ 3) 480
99mTc Sestamibi 95.772.0 (n ¼ 15) 95.372.0 (n ¼ 10) 96.572.0 (n ¼ 3) 490
99mTc Oxidronate 97.071.0 (n ¼ 15) 96.371.0 (n ¼ 10) 96.070.4 (n ¼ 3) X95
Results are reported as the mean7SD for the number of testing performed (n).
aAccording to the Ofﬁcial Pharmacopoeia (FU) in Italy.
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